NASDAQ:ANNX Annexon (ANNX) Stock Price, News & Analysis $1.48 -0.06 (-4.16%) As of 09:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Annexon Stock (NASDAQ:ANNX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Annexon alerts:Sign Up Key Stats Today's Range$1.58▼$1.5850-Day Range$1.38▼$3.4452-Week Range$1.29▼$7.85Volume319 shsAverage Volume1.80 million shsMarket Capitalization$161.93 millionP/E RatioN/ADividend YieldN/APrice Target$18.67Consensus RatingBuy Company OverviewAnnexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Read More… Remove Ads Annexon Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreANNX MarketRank™: Annexon scored higher than 52% of companies evaluated by MarketBeat, and ranked 526th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAnnexon has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnnexon has only been the subject of 1 research reports in the past 90 days.Read more about Annexon's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Annexon are expected to decrease in the coming year, from ($0.96) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Annexon is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Annexon is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnnexon has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Annexon's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.85% of the float of Annexon has been sold short.Short Interest Ratio / Days to CoverAnnexon has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Annexon has recently decreased by 25.90%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnnexon does not currently pay a dividend.Dividend GrowthAnnexon does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.85% of the float of Annexon has been sold short.Short Interest Ratio / Days to CoverAnnexon has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Annexon has recently decreased by 25.90%, indicating that investor sentiment is improving significantly. News and Social Media2.9 / 5News Sentiment1.26 News SentimentAnnexon has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Annexon this week, compared to 3 articles on an average week.Search InterestOnly 10 people have searched for ANNX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Annexon to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Annexon insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $77,300.00 in company stock.Percentage Held by Insiders12.67% of the stock of Annexon is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Annexon's insider trading history. Receive ANNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Annexon and its competitors with MarketBeat's FREE daily newsletter. Email Address ANNX Stock News HeadlinesWhy Annexon Inc. (ANNX) Went Down On Thursday?April 10, 2025 | msn.comAnnexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual MeetingApril 3, 2025 | globenewswire.comTrump’s betrayal exposed Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you ready for it?April 16, 2025 | Porter & Company (Ad)Here's Why We're Not Too Worried About Annexon's (NASDAQ:ANNX) Cash Burn SituationMarch 31, 2025 | finance.yahoo.comBank of America Securities Remains a Buy on Annexon Biosciences (ANNX)March 10, 2025 | markets.businessinsider.comAnnexon price target lowered to $11 from $12 at BofAMarch 10, 2025 | markets.businessinsider.comWells Fargo Reaffirms Their Buy Rating on Annexon Biosciences (ANNX)March 4, 2025 | markets.businessinsider.comAnnexon price target lowered to $20 from $30 at H.C. WainwrightMarch 4, 2025 | markets.businessinsider.comSee More Headlines ANNX Stock Analysis - Frequently Asked Questions How have ANNX shares performed this year? Annexon's stock was trading at $5.13 at the beginning of the year. Since then, ANNX shares have decreased by 71.1% and is now trading at $1.4850. View the best growth stocks for 2025 here. How were Annexon's earnings last quarter? Annexon, Inc. (NASDAQ:ANNX) posted its quarterly earnings results on Monday, March, 3rd. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.05. When did Annexon IPO? Annexon (ANNX) raised $150 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Cowen acted as the underwriters for the IPO. Who are Annexon's major shareholders? Annexon's top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.44%) and Park Avenue Securities LLC (0.08%). Insiders that own company stock include Bain Capital Life Sciences Inv, Douglas Love, Michael Overdorf, Dean Richard Artis, Jennifer Lew, Ted Yednock, Jamie Dananberg and William H Carson. View institutional ownership trends. How do I buy shares of Annexon? Shares of ANNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Annexon own? Based on aggregate information from My MarketBeat watchlists, some other companies that Annexon investors own include NVIDIA (NVDA), MercadoLibre (MELI), Advanced Micro Devices (AMD), Meta Platforms (META), Barrick Gold (GOLD), CRISPR Therapeutics (CRSP) and Energy Transfer (ET). Company Calendar Last Earnings3/03/2025Today4/16/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANNX CIK1528115 Webwww.annexonbio.com Phone650-822-5500Fax650-636-9773Employees60Year FoundedN/APrice Target and Rating Average Stock Price Target$18.67 High Stock Price Target$30.00 Low Stock Price Target$10.00 Potential Upside/Downside+1,112.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-134,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.99% Return on Assets-33.90% Debt Debt-to-Equity RatioN/A Current Ratio17.17 Quick Ratio17.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.20 per share Price / Book0.48Miscellaneous Outstanding Shares109,710,000Free Float93,089,000Market Cap$168.95 million OptionableOptionable Beta1.24 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:ANNX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annexon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annexon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.